These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24706368)

  • 1. MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
    Lodi A; Woods SM; Ronen SM
    NMR Biomed; 2014 Jun; 27(6):700-8. PubMed ID: 24706368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells.
    Lodi A; Woods SM; Ronen SM
    NMR Biomed; 2013 Mar; 26(3):299-306. PubMed ID: 22945392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.
    Beloueche-Babari M; Jackson LE; Al-Saffar NM; Workman P; Leach MO; Ronen SM
    Cancer Res; 2005 Apr; 65(8):3356-63. PubMed ID: 15833869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells.
    Ge X; Fu YM; Meadows GG
    Cancer Lett; 2002 May; 179(2):133-40. PubMed ID: 11888667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
    Su JS; Woods SM; Ronen SM
    NMR Biomed; 2012 Feb; 25(2):379-88. PubMed ID: 22253088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK inhibition leads to lysosome-mediated Na+/I- symporter protein degradation in human breast cancer cells.
    Zhang Z; Beyer S; Jhiang SM
    Endocr Relat Cancer; 2013 Apr; 20(2):241-50. PubMed ID: 23404856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
    Favata MF; Horiuchi KY; Manos EJ; Daulerio AJ; Stradley DA; Feeser WS; Van Dyk DE; Pitts WJ; Earl RA; Hobbs F; Copeland RA; Magolda RL; Scherle PA; Trzaskos JM
    J Biol Chem; 1998 Jul; 273(29):18623-32. PubMed ID: 9660836
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Gupta PK; Orlovskiy S; Arias-Mendoza F; Nelson DS; Nath K
    Cells; 2024 Jul; 13(14):. PubMed ID: 39056801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.
    Flores LG; Yeh HH; Soghomonyan S; Young D; Bankson J; Hu Q; Alauddin M; Huff V; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):175-85. PubMed ID: 22875335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H; Noguchi K; Murakami Y; Uehara Y
    Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of inhibitors of mitogen-activated protein kinase kinase on alpha(1B)-adrenoceptor phosphorylation.
    Alcántara-Hernández R; Adolfo García-Sáinz J
    Auton Autacoid Pharmacol; 2009 Jan; 29(1-2):13-23. PubMed ID: 19302552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.
    Alesiani D; Cicconi R; Mattei M; Bei R; Canini A
    Int J Oncol; 2009 Jun; 34(6):1727-35. PubMed ID: 19424591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
    MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP
    Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.
    Li Q; Chow AB; Mattingly RR
    J Pharmacol Exp Ther; 2010 Mar; 332(3):821-8. PubMed ID: 19952304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
    Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO
    Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
    Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.